CR10358A - Pirido[3,2-e] pirazinas, su uso como inhibidores de fosfodiesterasa 10, y procesos para prepararlos - Google Patents

Pirido[3,2-e] pirazinas, su uso como inhibidores de fosfodiesterasa 10, y procesos para prepararlos

Info

Publication number
CR10358A
CR10358A CR10358A CR10358A CR10358A CR 10358 A CR10358 A CR 10358A CR 10358 A CR10358 A CR 10358A CR 10358 A CR10358 A CR 10358A CR 10358 A CR10358 A CR 10358A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
processes
pirazinas
phosphodesterase
pirido
Prior art date
Application number
CR10358A
Other languages
English (en)
Spanish (es)
Inventor
Norbert Hofgen
Hans Stange
Barbara Langen
Rudolf Schindler
Thomas Pfeifer
Chris Rundfeldt
Ute Egerland
Original Assignee
Elbion Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elbion Gmbh filed Critical Elbion Gmbh
Publication of CR10358A publication Critical patent/CR10358A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CR10358A 2006-05-30 2008-10-10 Pirido[3,2-e] pirazinas, su uso como inhibidores de fosfodiesterasa 10, y procesos para prepararlos CR10358A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80924206P 2006-05-30 2006-05-30

Publications (1)

Publication Number Publication Date
CR10358A true CR10358A (es) 2009-01-07

Family

ID=38441604

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10358A CR10358A (es) 2006-05-30 2008-10-10 Pirido[3,2-e] pirazinas, su uso como inhibidores de fosfodiesterasa 10, y procesos para prepararlos

Country Status (21)

Country Link
US (2) US7550465B2 (https=)
EP (1) EP2021342A1 (https=)
JP (1) JP2009538853A (https=)
KR (1) KR20090013834A (https=)
CN (1) CN101454324A (https=)
AR (1) AR061206A1 (https=)
AU (1) AU2007267392A1 (https=)
BR (1) BRPI0712132A2 (https=)
CA (1) CA2651849A1 (https=)
CL (1) CL2007001554A1 (https=)
CR (1) CR10358A (https=)
GT (1) GT200800265A (https=)
IL (1) IL193740A0 (https=)
MX (1) MX2008014569A (https=)
NO (1) NO20085326L (https=)
PE (1) PE20080711A1 (https=)
RU (1) RU2008152440A (https=)
SV (1) SV2009003048A (https=)
TW (1) TW200817400A (https=)
WO (1) WO2007137820A1 (https=)
ZA (1) ZA200807517B (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200815436A (en) * 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
CA2671980C (en) * 2006-12-13 2015-05-05 Aska Pharmaceutical Co., Ltd. Quinoxaline derivatives
US20090143392A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Methods of Treating Obesity and Metabolic Disorders
US20090143361A1 (en) * 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
KR20100110804A (ko) * 2007-11-30 2010-10-13 와이어쓰 엘엘씨 포스포디에스테라제 10의 저해물질로서의 아릴 및 헤테로아릴 융합된 이미다조[1,5-ａ]피라진
EA018927B1 (ru) * 2008-05-07 2013-11-29 Х. Лундбекк А/С Способ лечения когнитивного расстройства, ассоциированного с шизофренией
US20100120762A1 (en) * 2008-11-07 2010-05-13 Wyeth Triazine derivatives as inhibitors of phosphodiesterases
CN103108548A (zh) * 2010-07-20 2013-05-15 昔勒尼药品公司 使用环酰胺衍生物治疗σ受体介导的病症的方法
WO2012012542A1 (en) * 2010-07-20 2012-01-26 Cyrenaic Pharmaceuticals, Inc. Methods of use of cyclic amide derivatives to treat schizophrenia
US9540379B2 (en) 2011-01-31 2017-01-10 Boehringer Ingelheim International Gmbh (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases
CN103476757A (zh) 2011-02-18 2013-12-25 阿勒根公司 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物
US9938269B2 (en) 2011-06-30 2018-04-10 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
JP2014526453A (ja) * 2011-09-09 2014-10-06 ハー・ルンドベック・アクチエゼルスカベット ピリジン化合物およびそれらの使用
US20130116241A1 (en) 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
AU2012334011A1 (en) 2011-11-09 2014-05-15 AbbVie Deutschland GmbH & Co. KG Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10A
MX361539B (es) 2012-04-25 2018-12-10 Takeda Pharmaceuticals Co Compuesto heterociclico nitrogenado.
EP2873669A4 (en) * 2012-07-13 2015-11-25 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
US20140045856A1 (en) * 2012-07-31 2014-02-13 Boehringer Ingelheim International Gmbh 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
UY34980A (es) 2012-08-17 2014-03-31 Abbvie Inc Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
EP2895489B1 (en) 2012-09-17 2017-10-18 AbbVie Deutschland GmbH & Co. KG Novel inhibitor compounds of phosphodiesterase type 10a
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US9790203B2 (en) 2012-11-26 2017-10-17 Abbvie Inc. Inhibitor compounds of phosphodiesterase type 10A
US9200005B2 (en) 2013-03-13 2015-12-01 AbbVie Deutschland GmbH & Co. KG Inhibitor compounds of phosphodiesterase type 10A
EP2975031A4 (en) 2013-03-14 2017-04-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN105209462A (zh) 2013-03-14 2015-12-30 艾伯维德国有限责任两合公司 磷酸二酯酶10a型的新型抑制剂化合物
JP6427491B2 (ja) 2013-07-03 2018-11-21 武田薬品工業株式会社 複素環化合物
ES2950424T3 (es) 2013-07-03 2023-10-09 Takeda Pharmaceuticals Co Compuesto de amida
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
US10189841B2 (en) 2015-11-20 2019-01-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
IL308650B2 (en) 2017-06-21 2025-08-01 Minerva Neurosciences Inc Gastro-resistant controlled release oral dosage forms
WO2020065583A1 (en) 2018-09-28 2020-04-02 Takeda Pharmaceutical Company Limited Balipodect for treating or preventing autism spectrum disorders
CN114524808B (zh) * 2022-02-21 2023-10-24 深圳市儿童医院 一种吡唑衍生物及其作为pde10抑制剂的用途
CN114524806B (zh) * 2022-02-22 2024-09-03 深圳市儿童医院 一种三氮唑衍生物及其作为pde10抑制剂的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055465A (en) * 1989-05-31 1991-10-08 Berlex Laboratories, Inc. Imidazoquinoxalinones, their aza analogs and process for their preparation
AU657986B2 (en) * 1991-06-14 1995-03-30 Pharmacia & Upjohn Company Imidazo(1,5-a)quinoxalines
DE19510965A1 (de) * 1995-03-24 1996-09-26 Asta Medica Ag Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung
US20030032579A1 (en) * 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
IL149106A0 (en) 2001-04-20 2002-11-10 Pfizer Prod Inc Therapeutic use of selective pde10 inhibitors

Also Published As

Publication number Publication date
ZA200807517B (en) 2009-06-24
GT200800265A (es) 2010-07-22
PE20080711A1 (es) 2008-06-14
RU2008152440A (ru) 2010-07-10
CL2007001554A1 (es) 2008-01-18
KR20090013834A (ko) 2009-02-05
JP2009538853A (ja) 2009-11-12
EP2021342A1 (en) 2009-02-11
TW200817400A (en) 2008-04-16
BRPI0712132A2 (pt) 2012-01-17
CN101454324A (zh) 2009-06-10
US20080027064A1 (en) 2008-01-31
NO20085326L (no) 2008-12-19
US20090239874A1 (en) 2009-09-24
AR061206A1 (es) 2008-08-13
US7550465B2 (en) 2009-06-23
MX2008014569A (es) 2008-12-03
CA2651849A1 (en) 2007-12-06
WO2007137820A1 (en) 2007-12-06
AU2007267392A1 (en) 2007-12-06
SV2009003048A (es) 2009-02-11
IL193740A0 (en) 2009-05-04

Similar Documents

Publication Publication Date Title
CR10358A (es) Pirido[3,2-e] pirazinas, su uso como inhibidores de fosfodiesterasa 10, y procesos para prepararlos
ECSP12008540A (es) PIRROL[2,3-b]PIRIDINAS Y PIRROL[2,3-b]PIRIMIDINAS HETEROARILO SUSTITUIDAS COMO INHIBIDORES DE QUINASAS JANUS
GT201300291A (es) Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias.
CR9781A (es) 1h-imidazopiridinas sustituidas con hidroxi y procedimientos
MX394094B (es) PYRAZOLO [1, 5-a] PIRIMIDINAS SUSTITUIDAS Y SU USO EN EL TRATAMIENTO DE TRASTORNOS MÉDICOS.
CO6531468A2 (es) Derivados de imidazo[1,2-b] piridazina y su uso como inhibidores de pde 10
ECSP11011113A (es) Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades
MX386924B (es) Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades.
CL2013001464A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina, como inhibidores de jak; composicion farmaceutica que los comprende; producto de combinacion; y su uso en el tratamiento de enfermedades mieloproliferativas, leucemia, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias, entre otras.
BR112012022650A8 (pt) derivados de imidazo [1,2-a]pirazina e seu uso como inibidores de pde10
CR9135A (es) Derivados novedosos pirrolidilo de compuestos heteroaromaticos
UY29781A1 (es) Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos
ECSP088121A (es) Derivados de pirrolo [2,3-b] piridina comoinhibidores de proteina cinasa
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
PA8806201A1 (es) Imidazo pirazinas fusionadas
MX2008012422A (es) Derivados de furano y tiofeno, pirrol substituido con pirimidinil y piridil como inhibidores de cinasa.
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
CL2012001027A1 (es) Compuestos derivados de 7-(fenilamina)-5-oxo-1,2,3,5-tetrahidro-imidazo[1,2-a]piridina, 7-(fenilamina)5-oxo-2,3-dihidro-5h-tiazolo[3,2-a]piridina, 7-(fenulaminas)-5-oxo-2,3-dihidro-2hoxazolo[3,2-a]piridina: composicion farmaceutica; utiles en el tratamiento de enfermedades, trastornos o sindrome asociado con la inhibicion mek.
MX2010007523A (es) Nuevos derivados de pirazolo[3,4-d]pirimidina como farmacos anticancer.
BR112014001665A2 (pt) compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz
ATE453646T1 (de) 3-substituierte n-(aryl- oder heteroaryl)pyrazoä1,5-aüpyrimidine als kinaseinhibitoren
CL2019001669A1 (es) Pirazolo[3,4-b]piridinas e imidazo[1,5-b]piridazinas como inhibidores de pde1.
ECSP088250A (es) Derivados de pirazol como agentes terapéuticos
CR8546A (es) DERIVADOS DE 1H-TIENO [2,3c] PIRAZOL UTILES COMO INHIBIDORES DE QUINASA
BR112018004347A2 (pt) derivados de éter cíclico de pirazolo[1,5-a]pirimidina-3-carboxiamida

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)